Prof. Dr. med. et phil. nat. Markus Jörger
Oberarzt Onkologie/Hämatologie
Mitarbeiter Wissenschaftliche Module CTU (Klinische Pharmakologie)
Leitende(r) Arzt/Ärztin
Medizinische Onkologie und Hämatologie · Dept. I
New antibody-drug conjugates (ADCs) in breast cancer-an overview of ADCs recently approved and in later stages of development.
Koster K, Huober J, Jörger M. New antibody-drug conjugates (ADCs) in breast cancer-an overview of ADCs recently approved and in later stages of development. Explor Target Antitumor Ther 2022; 3:27-36.
24.02.2022New antibody-drug conjugates (ADCs) in breast cancer-an overview of ADCs recently approved and in later stages of development.
24.02.2022Explor Target Antitumor Ther 2022; 3:27-36
Koster Kira-Lee, Huober Jens, Jörger Markus
Current status and future outlooks on therapeutic drug monitoring of fluorouracil.
Schmulenson E, Zimmermann N, Mikus G, Jörger M, Jaehde U. Current status and future outlooks on therapeutic drug monitoring of fluorouracil. Expert Opin Drug Metab Toxicol 2022; 17:1407-1422.
24.01.2022Current status and future outlooks on therapeutic drug monitoring of fluorouracil.
24.01.2022Expert Opin Drug Metab Toxicol 2022; 17:1407-1422
Schmulenson Eduard, Zimmermann Nigina, Mikus Gerd, Jörger Markus, Jaehde Ulrich
Developing a Nationwide Infrastructure for Therapeutic Drug Monitoring of Targeted Oral Anticancer Drugs: The ON-TARGET Study Protocol.
Mc Laughlin A, Schmulenson E, Teplytska O, Zimmermann S, Opitz P, Groenland S, Huitema A, Steeghs N, Müller L, Fuxius S, Illerhaus G, Jörger M, Mayer F, Fuhr U, Holdenrieder S, Hempel G, Scherf-Clavel O, Jaehde U, Kloft C, For The On-Target Study Consortium. Developing a Nationwide Infrastructure for Therapeutic Drug Monitoring of Targeted Oral Anticancer Drugs: The ON-TARGET Study Protocol. Cancers (Basel) 2021; 13
14.12.2021Developing a Nationwide Infrastructure for Therapeutic Drug Monitoring of Targeted Oral Anticancer Drugs: The ON-TARGET Study Protocol.
14.12.2021Cancers (Basel) 2021; 13
Mc Laughlin Anna M, Schmulenson Eduard, Teplytska Olga, Zimmermann Sebastian, Opitz Patrick, Groenland Stefanie L, Huitema Alwin D R, Steeghs Neeltje, Müller Lothar, Fuxius Stefan, Illerhaus Gerald, Jörger Markus, Mayer Frank, Fuhr Uwe, Holdenrieder Stefan, Hempel Georg, Scherf-Clavel Oliver, Jaehde Ulrich, Kloft Charlotte, For The On-Target Study Consortium
Local tumor microbial signatures and response to checkpoint blockade in non-small cell lung cancer.
Bösch M, Baty F, Albrich W, Flatz L, Rodriguez R, Rothschild S, Jörger M, Früh M, Brutsche M. Local tumor microbial signatures and response to checkpoint blockade in non-small cell lung cancer. Oncoimmunology 2021; 10:1988403.
10.12.2021Local tumor microbial signatures and response to checkpoint blockade in non-small cell lung cancer.
10.12.2021Oncoimmunology 2021; 10:1988403
Bösch Maximilian, Baty Florent, Albrich Werner, Flatz Lukas, Rodriguez Regulo, Rothschild Sacha I, Jörger Markus, Früh Martin, Brutsche Martin H
Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients.
Purde M, Niederer R, Wagner N, Diem S, Berner F, Hasan Ali O, Hillmann D, Bergamin I, Jörger M, Risch M, Niederhauser C, Lenz T, Früh M, Risch L, Semela D, Flatz L. Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients. J Cancer Res Clin Oncol 2021; 148:647-656.
07.12.2021Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients.
07.12.2021J Cancer Res Clin Oncol 2021; 148:647-656
Purde Mette-Triin, Niederer Rebekka, Wagner Nikolaus, Diem Stefan, Berner Fiamma, Hasan Ali Omar, Hillmann Dorothea, Bergamin Irina, Jörger Markus, Risch Martin, Niederhauser Christoph, Lenz Tobias L, Früh Martin, Risch Lorenz, Semela David, Flatz Lukas
Keratinocyte differentiation antigen-specific T cells in immune checkpoint inhibitor-treated NSCLC patients are associated with improved survival.
Berner F, Niederer R, Luimstra J, Pop O, Jochum A, Purde M, Hasan Ali O, Bomze D, Bauer J, Freudenmann L, Marcu A, Wolfschmitt E, Haen S, Gross T, Dubbelaar M, Abdou M, Baumgaertner P, Appenzeller C, Cicin-Sain C, Lenz T, Speiser D, Ludewig B, Driessen C, Jörger M, Früh M, Jochum W, Cozzio A, Rammensee H, Walz J, Neefjes J, Flatz L. Keratinocyte differentiation antigen-specific T cells in immune checkpoint inhibitor-treated NSCLC patients are associated with improved survival. Oncoimmunology 2021; 10:2006893.
27.11.2021Keratinocyte differentiation antigen-specific T cells in immune checkpoint inhibitor-treated NSCLC patients are associated with improved survival.
27.11.2021Oncoimmunology 2021; 10:2006893
Berner Fiamma, Niederer Rebekka, Luimstra Jolien J, Pop Oltin Tiberiu, Jochum Ann-Kristin, Purde Mette-Triin, Hasan Ali Omar, Bomze David, Bauer Jens, Freudenmann Lena Katharina, Marcu Ana, Wolfschmitt Eva-Maria, Haen Sebastian, Gross Thorben, Dubbelaar MariLisa, Abdou Marie-Therese, Baumgaertner Petra, Appenzeller Christina, Cicin-Sain Caroline, Lenz Tobias, Speiser Daniel E, Ludewig Burkhard, Driessen Christoph, Jörger Markus, Früh Martin, Jochum Wolfram, Cozzio Antonio, Rammensee Hans-Georg, Walz Juliane, Neefjes Jacques, Flatz Lukas
Precision Dosing of Targeted Therapies Is Ready for Prime Time
Groenland S, Verheijen R, Jörger M, Mathijssen R, Sparreboom A, Beijnen J, Beumer J, Steeghs N, Huitema A. Precision Dosing of Targeted Therapies Is Ready for Prime Time. Clin Cancer Res 2021; 27:6644-6652.
21.09.2021Precision Dosing of Targeted Therapies Is Ready for Prime Time
21.09.2021Clin Cancer Res 2021; 27:6644-6652
Groenland Stefanie L, Verheijen Remy B, Jörger Markus, Mathijssen Ron H J, Sparreboom Alex, Beijnen Jos H, Beumer Jan H, Steeghs Neeltje, Huitema Alwin D R
SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial
Rothschild S, Cathomas R, Ochsenbein A, Janthur W, Waibel C, Mach N, Froesch P, Buess M, Bohanes P, Godar G, Rusterholz C, Gonzalez M, Pless M, Mark M, Peters S, Zippelius A, Eboulet E, Savic Prince S, Betticher D, Bettini A, Früh M, Jörger M, Lardinois D, Gelpke H, Mauti L, Britschgi C, Weder W, Swiss Group for Clinical Cancer Research (SAKK). SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial. J Clin Oncol 2021; 39:2872-2880.
12.07.2021SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial
12.07.2021J Clin Oncol 2021; 39:2872-2880
Rothschild Sacha I, Cathomas Richard, Ochsenbein Adrian F, Janthur Wolf-Dieter, Waibel Christine, Mach Nicolas, Froesch Patrizia, Buess Martin, Bohanes Pierre, Godar Gilles, Rusterholz Corinne, Gonzalez Michel, Pless Miklos, Mark Michael, Peters Solange, Zippelius Alfred, Eboulet Eric I, Savic Prince Spasenija, Betticher Daniel, Bettini Adrienne, Früh Martin, Jörger Markus, Lardinois Didier, Gelpke Hans, Mauti Laetitia A, Britschgi Christian, Weder Walter, Swiss Group for Clinical Cancer Research (SAKK)
Computational Treatment Simulations to Assess the Need for Personalized Tamoxifen Dosing in Breast Cancer Patients of Different Biogeographical Groups
Mueller-Schoell A, Mikus G, Huisinga W, Jörger M, Schwab M, Mürdter T, van Dyk M, Klopp-Schulze L, Michelet R, Kloft C. Computational Treatment Simulations to Assess the Need for Personalized Tamoxifen Dosing in Breast Cancer Patients of Different Biogeographical Groups. Cancers (Basel) 2021; 13
18.05.2021Computational Treatment Simulations to Assess the Need for Personalized Tamoxifen Dosing in Breast Cancer Patients of Different Biogeographical Groups
18.05.2021Cancers (Basel) 2021; 13
Mueller-Schoell Anna, Mikus Gerd, Huisinga Wilhelm, Jörger Markus, Schwab Matthias, Mürdter Thomas E, van Dyk Madelé, Klopp-Schulze Lena, Michelet Robin, Kloft Charlotte
Drug-Induced Pseudo-Central Serous Chorioretinopathy in Carcinoma Patients
Jung S, Valmaggia C, Jörger M, Todorova M. Drug-Induced Pseudo-Central Serous Chorioretinopathy in Carcinoma Patients. Klin Monbl Augenheilkd 2021; 238:403-409.
30.04.2021Drug-Induced Pseudo-Central Serous Chorioretinopathy in Carcinoma Patients
30.04.2021Klin Monbl Augenheilkd 2021; 238:403-409
Jung Sascha, Valmaggia Christophe, Jörger Markus, Todorova Margarita
Drug-Induced Pseudo-Central Serous Chorioretinopathy in Carcinoma Patients
Jung S, Valmaggia C, Jörger M, Todorova M. Drug-Induced Pseudo-Central Serous Chorioretinopathy in Carcinoma Patients. Klin Monbl Augenheilkd 2021; 238:403-409.
30.04.2021Drug-Induced Pseudo-Central Serous Chorioretinopathy in Carcinoma Patients
30.04.2021Klin Monbl Augenheilkd 2021; 238:403-409
Jung Sascha, Valmaggia Christophe, Jörger Markus, Todorova Margarita
Pembrolizumab-Associated CD8 Vasculitic Mononeuritis Multiplex in a Patient With Mesothelioma
Baldauf M, Jörger M, Flatz L, Rodriguez R, Frank S, Felbecker A, Hundsberger T. Pembrolizumab-Associated CD8 Vasculitic Mononeuritis Multiplex in a Patient With Mesothelioma. Neurol Neuroimmunol Neuroinflamm 2021; 8
06.04.2021Pembrolizumab-Associated CD8 Vasculitic Mononeuritis Multiplex in a Patient With Mesothelioma
06.04.2021Neurol Neuroimmunol Neuroinflamm 2021; 8
Baldauf Michaela, Jörger Markus, Flatz Lukas, Rodriguez Regulo, Frank Stephan, Felbecker Ansgar, Hundsberger Thomas
Tumour neoantigen mimicry by microbial species in cancer immunotherapy
Bösch M, Baty F, Rothschild S, Tamm M, Jörger M, Früh M, Brutsche M. Tumour neoantigen mimicry by microbial species in cancer immunotherapy. Br J Cancer 2021; 125:313-323.
06.04.2021Tumour neoantigen mimicry by microbial species in cancer immunotherapy
06.04.2021Br J Cancer 2021; 125:313-323
Bösch Maximilian, Baty Florent, Rothschild Sacha I, Tamm Michael, Jörger Markus, Früh Martin, Brutsche Martin
Radiotherapy for thymic epithelial tumours: a review
Süveg K, Putora P, Jörger M, Iseli T, Fischer G, Ammann K, Glatzer M. Radiotherapy for thymic epithelial tumours: a review. Transl Lung Cancer Res 2021; 10:2088-2100.
01.04.2021Radiotherapy for thymic epithelial tumours: a review
01.04.2021Transl Lung Cancer Res 2021; 10:2088-2100
Süveg Krisztian, Putora Paul Martin, Jörger Markus, Iseli Thomas, Fischer Galina Farina, Ammann Karlheinz, Glatzer Markus
Association of Supporting Trial Evidence and Reimbursement for Off-Label Use of Cancer Drugs
Herbrand A, Hemkens L, Novak U, Moffa G, Jörger M, Hoogkamer A, Diem S, Goldkuhle M, Ewald H, Briel M, Schmitt A, Kasenda B. Association of Supporting Trial Evidence and Reimbursement for Off-Label Use of Cancer Drugs. JAMA Netw Open 2021; 4:e210380.
01.03.2021Association of Supporting Trial Evidence and Reimbursement for Off-Label Use of Cancer Drugs
01.03.2021JAMA Netw Open 2021; 4:e210380
Herbrand Amanda Katherina, Hemkens Lars G, Novak Urban, Moffa Giusi, Jörger Markus, Hoogkamer Anouk, Diem Stefan, Goldkuhle Marius, Ewald Hannah, Briel Matthias, Schmitt Andreas M, Kasenda Benjamin
Simulation-Based Assessment of the Impact of Non-Adherence on Endoxifen Target Attainment in Different Tamoxifen Dosing Strategies
Mueller-Schoell A, Mikus G, Huisinga W, Jörger M, Schwab M, Mürdter T, van Dyk M, Michelet R, Klopp-Schulze L, Kloft C. Simulation-Based Assessment of the Impact of Non-Adherence on Endoxifen Target Attainment in Different Tamoxifen Dosing Strategies. Pharmaceuticals (Basel) 2021; 14
03.02.2021Simulation-Based Assessment of the Impact of Non-Adherence on Endoxifen Target Attainment in Different Tamoxifen Dosing Strategies
03.02.2021Pharmaceuticals (Basel) 2021; 14
Mueller-Schoell Anna, Mikus Gerd, Huisinga Wilhelm, Jörger Markus, Schwab Matthias, Mürdter Thomas E, van Dyk Madelé, Michelet Robin, Klopp-Schulze Lena, Kloft Charlotte
Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors
Hurkmans D, Mathijssen R, Aerts J, van der Veldt A, Schreurs M, van der Leest C, Koch B, Debets R, Jörger M, Wijkhuijs A, Basak E, Putter L, de Joode K, Sassen S, Koolen S. Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors. J Immunother Cancer 2021; 9
01.01.2021Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors
01.01.2021J Immunother Cancer 2021; 9
Hurkmans Daan P, Mathijssen Ron H J, Aerts Joachim G J V, van der Veldt Astrid A M, Schreurs Marco W J, van der Leest Cor H, Koch Birgit C P, Debets Reno, Jörger Markus, Wijkhuijs Annemarie J M, Basak Edwin A, Putter Lisanne, de Joode Karlijn, Sassen Sebastiaan D T, Koolen Stijn L W
Role of TDM-based dose adjustments for taxane anticancer drugs
Muth M, Ojara F, Kloft C, Jörger M. Role of TDM-based dose adjustments for taxane anticancer drugs. Br J Clin Pharmacol 2020; 87:306-316.
18.12.2020Role of TDM-based dose adjustments for taxane anticancer drugs
18.12.2020Br J Clin Pharmacol 2020; 87:306-316
Muth Marsilla, Ojara Francis Williams, Kloft Charlotte, Jörger Markus
Fluoropyrimidine chemotherapy: recommendations for DPYD genotyping and therapeutic drug monitoring of the Swiss Group of Pharmacogenomics and Personalised Therapy
Hamzic S, Aebi S, Jörger M, Montemurro M, Ansari M, Amstutz U, Largiadèr C. Fluoropyrimidine chemotherapy: recommendations for DPYD genotyping and therapeutic drug monitoring of the Swiss Group of Pharmacogenomics and Personalised Therapy. Swiss Med Wkly 2020; 150:w20375.
24.11.2020Fluoropyrimidine chemotherapy: recommendations for DPYD genotyping and therapeutic drug monitoring of the Swiss Group of Pharmacogenomics and Personalised Therapy
24.11.2020Swiss Med Wkly 2020; 150:w20375
Hamzic Seid, Aebi Stefan, Jörger Markus, Montemurro Michael, Ansari Marc, Amstutz Ursula, Largiadèr Carlo
Predictive and Prognostic Value of DNA Damage Response Associated Kinases in Solid Tumors
Gachechiladze M, Škarda J, Bouchalova K, Soltermann A, Jörger M. Predictive and Prognostic Value of DNA Damage Response Associated Kinases in Solid Tumors. Front Oncol 2020; 10:581217.
03.11.2020Predictive and Prognostic Value of DNA Damage Response Associated Kinases in Solid Tumors
03.11.2020Front Oncol 2020; 10:581217
Gachechiladze Mariam, Škarda Josef, Bouchalova Katerina, Soltermann Alex, Jörger Markus